Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta
- PMID: 25233970
Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta
Abstract
Objective: To assess the beneficial effect of intravenous pamidronate treatment in children with osteogenesis imperfecta (OI).
Study design: Experimental study.
Place and duration of study: Endocrine Unit at the National Institute of Child Health, Karachi, Pakistan, from January 2007 to December 2011.
Methodology: All children diagnosed with osteogenesis imperfecta on the basis of repeated spontaneous fractures and typical radiological findings registered during the study period, were included in this study. Pamidronate therapy were offered to those with more than 3 fractures per year or had platyspondyly. Pamidronate disodium was diluted in isotonic saline and administered by slow ravenous infusion over 3 hours in a dosage 1 mg/kg/day for 3 consecutive days 3 monthly for 2 years. Fracture rate, bone mineral density (BMD), mobility score, wellbeing and pain episodes were evaluated at baseline and 2 years after the treatment. Good response was defined as less than 2 fractures per year or mobility score improvement and poor response as more than 2 fracture per year with mobility score less than 2.
Results: Seventy two patients were included in this study. There were 40 boys and 32 girls with mean age of 3.64 ± 3.2 years. The annual fracture rate decreased overall from 5.8 ± 1.61 to 0.6 ± 0.93 (p < 0.001). BMD Z-score improved from -5.3 ± 1.74 to -1.7 ± 0.72 (p < 0.001). Mobility score was 0.94 ± 1.30 at baseline and 2.5 ± 1.02 at the end of the treatment (p < 0.001). Wellbeing gained from 3.63 ± 1.44 to 7.8 ± 1.18 (p < 0.001) and pain episode improved from 24.1 ± 8.15 to 2.7 ± 8.31 (p < 0.001). Good response was noted in 92% of patients and poor response in 8% patients.
Conclusion: Bisphosphonate seems to be an effective symptomatic treatment for children with osteogenesis imperfecta irrespective of severity of mutation or clinical phenotype. Cyclical bisphosphonate therapy has a positive effect on fracture rate, BMD, mobility score, wellbeing and pain episode.
Similar articles
-
Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.Bone. 2007 Mar;40(3):638-44. doi: 10.1016/j.bone.2006.10.010. Epub 2006 Nov 28. Bone. 2007. PMID: 17127117 Clinical Trial.
-
Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.Calcif Tissue Int. 2010 Aug;87(2):120-9. doi: 10.1007/s00223-010-9383-y. Epub 2010 Jun 11. Calcif Tissue Int. 2010. PMID: 20544187 Clinical Trial.
-
Bisphosphonate therapy for osteogenesis imperfecta.Cochrane Database Syst Rev. 2014 Jul 23;(7):CD005088. doi: 10.1002/14651858.CD005088.pub3. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2016 Oct 19;10:CD005088. doi: 10.1002/14651858.CD005088.pub4. PMID: 25054949 Updated. Review.
-
Cyclic pamidronate therapy in children with osteogenesis imperfecta.J Pediatr Endocrinol Metab. 2010 Jan-Feb;23(1-2):73-80. doi: 10.1515/jpem.2010.23.1-2.73. J Pediatr Endocrinol Metab. 2010. PMID: 20432809 Clinical Trial.
-
Bisphosphonate therapy for osteogenesis imperfecta.Cochrane Database Syst Rev. 2016 Oct 19;10(10):CD005088. doi: 10.1002/14651858.CD005088.pub4. Cochrane Database Syst Rev. 2016. PMID: 27760454 Free PMC article. Review.
Cited by
-
Optimising Health-Related Quality of Life in Children With Osteogenesis Imperfecta.Calcif Tissue Int. 2024 May 2. doi: 10.1007/s00223-024-01205-4. Online ahead of print. Calcif Tissue Int. 2024. PMID: 38695871 Review.
-
The patient clinical journey and socioeconomic impact of osteogenesis imperfecta: a systematic scoping review.Orphanet J Rare Dis. 2023 Feb 22;18(1):34. doi: 10.1186/s13023-023-02627-3. Orphanet J Rare Dis. 2023. PMID: 36814274 Free PMC article. Review.
-
Osteogenesis imperfecta and pregnancy: a case report.J Med Case Rep. 2019 Dec 11;13(1):363. doi: 10.1186/s13256-019-2296-0. J Med Case Rep. 2019. PMID: 31822291 Free PMC article.
-
Effect of Bisphosphonates on Function and Mobility Among Children With Osteogenesis Imperfecta: A Systematic Review.JBMR Plus. 2019 Oct 18;3(10):e10216. doi: 10.1002/jbm4.10216. eCollection 2019 Oct. JBMR Plus. 2019. PMID: 31687649 Free PMC article.
-
Application of anti-Sclerostin therapy in non-osteoporosis disease models.Bone. 2017 Mar;96:18-23. doi: 10.1016/j.bone.2016.10.018. Epub 2016 Oct 22. Bone. 2017. PMID: 27780792 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials